Wed, Mar 4, 2015, 3:47 PM EST - U.S. Markets close in 13 mins.

Recent

% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

dcoronaus 7 posts  |  Last Activity: Feb 26, 2015 8:41 AM Member since: Jul 6, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Novartis HDACi approved

    by aecooter33 Feb 24, 2015 9:50 AM
    dcoronaus dcoronaus Feb 24, 2015 5:51 PM Flag

    Novartis International AG / Novartis receives FDA approval of Farydak(R), the first HDAC inhibitor for patients with multiple myeloma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
    - Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1]
    - Farydak prolonged median PFS benefit when used with bortezomib and dexamethasone combination versus combination alone (from 6 to 11 months)[1]
    - Multiple myeloma is an incurable blood cancer and there is an urgent need for new treatments[2]
    - Farydak is approved under FDA's accelerated approval program; regulatory applications are underway in the EU, Japan and worldwide

    Sentiment: Strong Buy

  • Reply to

    The significance of the AML study.

    by sdrawkcabeman Dec 9, 2014 3:36 PM
    dcoronaus dcoronaus Feb 21, 2015 11:08 AM Flag

    nice,please give me your take on MEIP with results out next month
    Pracinostat, a potential best-in-class, oral HDAC inhibitor for MDS and AML

  • dcoronaus by dcoronaus Feb 7, 2015 11:03 AM Flag

    VICTORIANS with Alzheimer’s disease are the first in the world to receive a new drug aiming to revolutionise treatment of the most common form of dementia.
    http://www.heraldsun.com.au/news/victoria/miracle-hope-in-victorian-trial-of-new-alzheimers-pill/story-fni0fit3-1227198851505?nk=b0135a620f41a538bd04226e71bd579a

  • dcoronaus dcoronaus Feb 7, 2015 10:55 AM Flag

    According to the Cleveland Plain Dealer, Smith, a prolific and outspoken researcher on Alzheimer’s disease and the biology of aging, was walking home at about 2 a.m. from an early Christmas party at a local tavern, when a man, who had apparently been at the tavern as well that night, struck him from behind and left the scene. Another motorist noticed the body of a man lying in the road, notified the police, and Smith was pronounced dead at a local hospital shortly thereafter. Incredibly, the driver was later found dead in his home or his car, according to various early news reports (see, e.g., The News-Herald)

  • "Eli Lilly is one of numerous drug companies, including Pfizer, Elan, Bristol-Myers Squibb and others, who are betting that stopping production of amyloid clumps in the brains of Alzheimer’s patients will slow the disease. All along, a handful of researchers have predicted that amyloid-blocking drugs could actually make the disease worse. One critic is Mark Smith at Case-Western-Reserve University in Cleveland.
    here is what he said in 2008:
    Others say the Alzheimer’s field has it backwards. Far from being harmful, amyloid is “actually a response to injury that the brain secretes to protect itself, like a scar,” argues Mark Smith, a neuroscientist at Case Western Reserve University. By removing it, “you will make the disease worse.” Amyloid deposits are often found near cerebral blood vessels, hinting that amyloid may act as a sealant for damaged blood vessels."

  • The drug, Namzaric is designed to treat moderate-to-severe dementia in Alzheimer's patients by combining in a single capsule memantine and donepezil — ingredients in two drugs that are often prescribed together
    Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Both are in use for Alzheimer's-related dementia
    AVXL will rock

LLY
70.6401+0.2701(+0.38%)3:47 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.